| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Chanson, J Timsit, C Masquet, A Warnet, P J Guillausseau, P Birman, A G Harris, J Lubetzk. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of internal medicine. vol 113. issue 12. 1990-12-27. PMID:2240917. |
cardiovascular effects of the somatostatin analog octreotide in acromegaly. |
1990-12-27 |
2023-08-11 |
Not clear |
| P Chanson, J Timsit, C Masquet, A Warnet, P J Guillausseau, P Birman, A G Harris, J Lubetzk. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of internal medicine. vol 113. issue 12. 1990-12-27. PMID:2240917. |
to determine the cardiovascular effects of the somatostatin analog octreotide in patients with acromegaly. |
1990-12-27 |
2023-08-11 |
Not clear |
| L Fredstorp, A Harris, G Haas, S Werne. Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects. The Journal of clinical endocrinology and metabolism. vol 71. issue 5. 1990-12-10. PMID:2229278. |
short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects. |
1990-12-10 |
2023-08-11 |
Not clear |
| M C Gelato, E Oldfield, D L Loriaux, G R Merria. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion. The Journal of clinical endocrinology and metabolism. vol 71. issue 3. 1990-10-09. PMID:2118536. |
these results indicate that gh release is episodic under basal conditions and during continuous ghrh infusion in both acromegalic and normal subjects, indicating the importance of other modulators of gh release, such as somatostatin, which may remain pulsatile even in acromegaly. |
1990-10-09 |
2023-08-11 |
human |
| Y F Shi, A G Harris, X F Zhu, J Y Den. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients. Clinical endocrinology. vol 32. issue 6. 1990-09-20. PMID:2200620. |
ten patients (seven women, three men) with active acromegaly, five previously treated and five newly diagnosed, were included in an open-label prospective trial of 3 daily subcutaneous injections of the long-acting somatostatin analogue sms 201-995 (sandostatin) at increasing doses in order to obtain maximum growth hormone (gh) suppression. |
1990-09-20 |
2023-08-11 |
Not clear |
| S Itoh, K Tanaka, M Kumage, N Shimiz. Effects of a long-acting somatostatin analogue on pituitary-adrenocortical secretion in normal human subjects. Endocrinologia japonica. vol 37. issue 1. 1990-09-18. PMID:2166654. |
a potent and long-acting somatostatin analogue, sms 201-995 (sms) is currently employed for the treatment of various diseases with hypersecretion of hormones such as acromegaly and gastrinoma. |
1990-09-18 |
2023-08-11 |
human |
| P Pagesy, J Y Li, F Rentier-Delrue, O Delalande, Y Le Bouc, M Kujas, D Joubert, J Martial, F Peillo. Growth hormone and somatostatin gene expression in pituitary adenomas with active acromegaly and minimal plasma growth hormone elevation. Acta endocrinologica. vol 122. issue 6. 1990-08-24. PMID:1695808. |
growth hormone and somatostatin gene expression in pituitary adenomas with active acromegaly and minimal plasma growth hormone elevation. |
1990-08-24 |
2023-08-11 |
Not clear |
| J Nicholls, D Wynick, J Domin, L M Sandler, S R Bloo. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. Clinical endocrinology. vol 32. issue 5. 1990-08-15. PMID:2364560. |
pharmacokinetics of the long-acting somatostatin analogue octreotide (sms 201-995) in acromegaly. |
1990-08-15 |
2023-08-11 |
human |
| b' V Popovi\\xc4\\x87, M Nesovi\\xc4\\x87, D Mi\\xc4\\x87i\\xc4\\x87, A Kendereski, P Djordjevi\\xc4\\x87, D Manojlovi\\xc4\\x87, J Mi\\xc4\\x87i\\xc4\\x8. A comparison among the effectiveness of growth hormone suppression in active acromegaly of bromocriptine and long acting somatostatin analogue (SMS 201-995). Experimental and clinical endocrinology. vol 95. issue 2. 1990-08-13. PMID:1973122.' |
a comparison among the effectiveness of growth hormone suppression in active acromegaly of bromocriptine and long acting somatostatin analogue (sms 201-995). |
1990-08-13 |
2023-08-11 |
Not clear |
| b' V Popovi\\xc4\\x87, M Nesovi\\xc4\\x87, D Mi\\xc4\\x87i\\xc4\\x87, A Kendereski, P Djordjevi\\xc4\\x87, D Manojlovi\\xc4\\x87, J Mi\\xc4\\x87i\\xc4\\x8. A comparison among the effectiveness of growth hormone suppression in active acromegaly of bromocriptine and long acting somatostatin analogue (SMS 201-995). Experimental and clinical endocrinology. vol 95. issue 2. 1990-08-13. PMID:1973122.' |
the aim of our study was to compare the effectiveness of bromocriptine vs. long acting somatostatin analogue (sms 201-995) on growth hormone suppression in active acromegaly. |
1990-08-13 |
2023-08-11 |
Not clear |
| A B Atkinson, J A McKnight, D R McCance, P M Bel. Somatostatin analogue (SMS 201-995) in resistant acromegaly: a preliminary report. Hormone research. vol 33 Suppl 1. 1990-07-27. PMID:2358295. |
somatostatin analogue (sms 201-995) in resistant acromegaly: a preliminary report. |
1990-07-27 |
2023-08-11 |
Not clear |
| W E de Lange, A J Verhoeff, W J Sluiter, H Doorenbo. Hypogonadism in untreated male normoprolactinaemic acromegalics. The Netherlands journal of medicine. vol 36. issue 3-4. 1990-07-24. PMID:1972548. |
although we were unable to elicit a similar reaction pattern of the gnrh-gonadotrophins-testosterone axis following administration of biosynthetic methionyl-hgh, it is suggested that suppression of testicular function in untreated acromegaly without other endocrine disturbances may be partly caused by increased somatostatin production. |
1990-07-24 |
2023-08-11 |
Not clear |
| M D Page, M E Millward, A Taylor, M Preece, M Hourihan, R Hall, M F Scanlo. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide. The Quarterly journal of medicine. vol 74. issue 274. 1990-07-03. PMID:2111918. |
long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide. |
1990-07-03 |
2023-08-11 |
Not clear |
| S Natori, H Iguchi, M Ohashi, R Nakao, S R Bloom, H Nawat. Effect of octapeptide somatostatin analogue (SMS 201-995) on plasma 7B2 (a neuroendocrine polypeptide) levels in patients with acromegaly. Clinical endocrinology. vol 32. issue 1. 1990-06-07. PMID:2331811. |
effect of octapeptide somatostatin analogue (sms 201-995) on plasma 7b2 (a neuroendocrine polypeptide) levels in patients with acromegaly. |
1990-06-07 |
2023-08-11 |
human |
| S Natori, H Iguchi, M Ohashi, R Nakao, S R Bloom, H Nawat. Effect of octapeptide somatostatin analogue (SMS 201-995) on plasma 7B2 (a neuroendocrine polypeptide) levels in patients with acromegaly. Clinical endocrinology. vol 32. issue 1. 1990-06-07. PMID:2331811. |
we studied the sequential changes of plasma levels of immunoreactive '7b2' (ir-7b2), a neuroendocrine polypeptide, after a subcutaneous injection of 50 micrograms of synthetic octapeptide somatostatin analogue (sms 201-995) in seven patients with acromegaly due to gh-producing pituitary adenoma. |
1990-06-07 |
2023-08-11 |
human |
| P A van Liessum, L M Swinkels, G F Pieters, A A Ross, A G Smals, T J Benraad, P W Kloppenbor. Lack of antibody formation during long-term subcutaneous treatment with the somatostatin analogue octreotide in acromegaly. Acta endocrinologica. vol 122. issue 3. 1990-05-15. PMID:2183534. |
lack of antibody formation during long-term subcutaneous treatment with the somatostatin analogue octreotide in acromegaly. |
1990-05-15 |
2023-08-11 |
human |
| P I Salmela, H Juustila, J Pyhtinen, K Jokinen, M Alavaikko, A Ruokone. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly. The Journal of clinical endocrinology and metabolism. vol 70. issue 4. 1990-05-10. PMID:2180976. |
ten patients with active acromegaly, six with a poor response to previous therapies and four newly diagnosed, were treated with the long-acting somatostatin analog octreotide (sandostatin; 200-500 micrograms/day, sc, twice or three times daily) for 6-15 months. |
1990-05-10 |
2023-08-11 |
Not clear |
| E Roti, R Minelli, E Gardini, M Salvi, L Bianconi, L Balducci, A Manfredi, L E Braverma. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis. Journal of endocrinological investigation. vol 13. issue 1. 1990-05-01. PMID:2319110. |
the long-acting somatostatin analogue sms 201-995 has been used efficaciously in the therapy of metastatic carcinoid tumor, vasoactive intestinal peptide producing islet cell carcinoma, acromegaly, and tsh secreting pituitary tumors. |
1990-05-01 |
2023-08-11 |
Not clear |
| A R McGregor, W D Troughton, R A Donald, E A Espine. Effect of the somatostatin analogue SMS 201-995 on faecal fat excretion in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 22. issue 1. 1990-04-05. PMID:1968417. |
effect of the somatostatin analogue sms 201-995 on faecal fat excretion in acromegaly. |
1990-04-05 |
2023-08-11 |
Not clear |
| S Esnault, C Merceur, V Kerlan, S H Tea, J C le Mevel, J P Bercovici, D Mabi. [Long-term effects of treatment with SMS 201-995 on sleep apnea syndrome associated with acromegaly]. Neurophysiologie clinique = Clinical neurophysiology. vol 19. issue 5. 1990-02-26. PMID:2615748. |
a 60-year-old woman with acromegaly associated with sleep apnea was treated with the somatostatin analogue sms 201-995 (sandoz) for several months. |
1990-02-26 |
2023-08-11 |
Not clear |